{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:45:53Z","timestamp":1767134753277,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":22,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006097","type":"reference-entry","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T16:38:24Z","timestamp":1153240704000},"source":"Crossref","is-referenced-by-count":13,"title":["Natalizumab for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"JK","family":"MacDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JWD","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD006097-BIB1|cit1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn's disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD006097-BIB2|cit2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/gast.2001.26260","article-title":"A randomized placebo-controlled trial of humanized monoclonal antibody to alpha4 integrin in active Crohn's disease","volume":"121","author":"Gordon","year":"2001","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD006097-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1002\/14651858.CD006097-BIB4|cit4","unstructured":"ENCORE (Elan Pharmaceuticals Inc). A phase III, international, double blind, placebo-controlled study at 114 sites. Ongoing study"},{"issue":"4","key":"10.1002\/14651858.CD006097-BIB5|cit5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMc055235","article-title":"Natalizumab and progressive multifocal leukoencephalopathy","volume":"353","author":"Adelman","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD006097-BIB6|cit6","article-title":"Assessment of study quality. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]; Section 6","author":"Alderson","year":"2004","journal-title":"The Cochrane Library"},{"issue":"4","key":"10.1002\/14651858.CD006097-BIB7|cit7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab--unforseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD006097-BIB8|cit8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"issue":"22","key":"10.1002\/14651858.CD006097-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in treatment assignment in controlled clinical trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/14651858.CD006097-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD006097-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1002\/14651858.CD006097-BIB12|cit12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-Demasters","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD006097-BIB13|cit13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/14651858.CD006097-BIB14|cit14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"9128","key":"10.1002\/14651858.CD006097-BIB15|cit15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD006097-BIB16|cit16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1172\/JCI116575","article-title":"Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody","volume":"92","author":"Podolsky","year":"1993","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1002\/14651858.CD006097-BIB17|cit17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD006097-BIB18|cit18","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1002\/14651858.CD006097-BIB19|cit19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD006097-BIB20|cit20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.53.3.466","article-title":"The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group","volume":"53","author":"Tubridy","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006097-BIB21|cit21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Assche","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/14651858.CD006097-BIB22|cit22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006097.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:54:56Z","timestamp":1628531696000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006097"}},"subtitle":[],"editor":[{"given":"John","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2006,7,19]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006097","relation":{},"subject":[],"published":{"date-parts":[[2006,7,19]]}}}